ELISpot

Feline IFN-γ Kit

Catalog Number EL764

For the quantitative determination of the frequency of cells releasing feline Interferon gamma (IFN- γ).

This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures.

TABLE OF CONTENTS

SECTION	PAGE
INTRODUCTION	1
PRINCIPLE OF THE ASSAY	2
LIMITATIONS OF THE PROCEDURE	2
TECHNICAL HINTS	2
ELISPOT SCHEMATIC	
MATERIALS PROVIDED & STORAGE CONDITIONS	4
OTHER SUPPLIES REQUIRED	
PRECAUTIONS	
REAGENT PREPARATION	
SAMPLE PREPARATION	
ASSAY PROCEDURE	
CALCULATION OF RESULTS	
REPRODUCIBILITY DATA	
TROUBLESHOOTING GUIDE	8
REFERENCES	9
ΡΙ ΔΤΕ Ι ΔΥΟΙΙΤ	10

MANUFACTURED AND DISTRIBUTED BY:

USA & Canada | R&D Systems, Inc.

614 McKinley Place NE, Minneapolis, MN 55413, USA TEL: (800) 343-7475 (612) 379-2956 FAX: (612) 656-4400 E-MAIL: info@RnDSystems.com

DISTRIBUTED BY:

UK & Europe | R&D Systems Europe, Ltd.

19 Barton Lane, Abingdon Science Park, Abingdon OX14 3NB, UK TEL: +44 (0)1235 529449 FAX: +44 (0)1235 533420 E-MAIL: info@RnDSystems.co.uk

China | R&D Systems China Co., Ltd.

24A1 Hua Min Empire Plaza, 726 West Yan An Road, Shanghai PRC 200050 TEL: +86 (21) 52380373 FAX: +86 (21) 52371001 E-MAIL: info@RnDSystemsChina.com.cn

INTRODUCTION

Interferon-gamma (IFN-γ, also known as type II interferon) is an important immunoregulatory cytokine that was originally identified through its anti-viral activity (1). It plays key roles in host defense through its anti-viral, anti-proliferative and immunoregulatory activities (2-5). IFN-γ induces the production of cytokines and upregulates the expression of various membrane proteins including class I and II MHC antigens, Fc receptors, leukocyte adhesion molecules and B7 family antigens on various cell types. It is also a potent activator of macrophage effector functions. IFN-γ potentiates an immunoglobulin (Ig) by B cells and promotes the synthesis of IgG over other Ig classes. IFN-γ also influences T-helper cell phenotype development by inhibiting Th2 differentiation and stimulating Th1 development (2-5).

Various cell types produce IFN- γ including dendritic epidermal/ $\gamma\delta$ T cells, keratinocytes, peripheral blood $\gamma\delta$ T cells, mast cells, neurons, CD8+T cells, macrophages, B cells, neutrophils, NK cells, CD4+T cells (16) and testicular spermatids (6-17). The production of IFN- γ is upregulated synergistically by IL-12, IL-18, and IL-23 (18-21). Feline IFN- γ cDNA encodes a 167 amino acid (aa) residue precursor protein that contains a 20 aa signal sequence that is cleaved to generate a 147 aa residue mature cat IFN- γ (22). Feline IFN- γ is presumably a noncovalently linked homodimer (3). In the mature segment, feline IFN- γ is 40%, 41%, and 63% aa identical to rat, mouse and human IFN- γ , respectively (23-27).

The functional IFN- γ receptor complex consists of two distinct subunits (28). The α subunit (IFN- γ R1) binds IFN- γ with high affinity and species-specificity. The β subunit (IFN- γ R2, also known as AF-1 or accessory factor-1) interacts with the IFN- γ -occupied α subunit in a species-specific manner and participates in JAK-STAT mediated signal transduction. Although the functional receptor is thought to consist of homodimeric IFN- γ in combination with two α chains and two β chains, there are reports of additional subunits being involved in cell signaling (28-31). Whereas the α chain is expressed constitutively on many cell types, the tightly regulated expression of the β chain correlates with an IFN- γ responsive state (28).

The Feline IFN-γ ELISpot assay is designed for the detection of IFN-γ secreting cells at the single cell level, and it can be used to quantify the frequency of cat IFN-γ secreting cells. ELISpot assays are well suited for monitoring immune responses to various stimuli, treatments and therapies, and they have been used for the quantitation of antigen-specific CD4+ and/or CD8+ T cell responses. Other methods for the assessment of antigen-specific T cell responses, such as the chromium release assay with quantitation by limiting dilution, are tedious and require previous *in vitro* expansion of T cells for several days. These assays typically are not suitable for measuring infrequent T cell responses that occur at less than 1 in 1000. ELISpot assays are highly reproducible and sensitive, and can be used to measure responses with frequencies well below 1 in 100,000. ELISpot assays do not require prior *in vitro* expansion of T cells, and they are suitable for high-throughput analysis using only small volumes of primary cells. As such, ELISpot assays are useful tools for research in areas as diverse as antigen recognition, vaccine development, cytokine secretion and the monitoring of various clinical trials.

PRINCIPLE OF THE ASSAY

The enzyme-linked immunospot (ELISpot) assay was originally developed for the detection of individual B cells secreting antigen-specific antibodies (32, 33). This method has since been adapted for the detection of individual cells secreting specific cytokines or other antigens (34, 35). ELISpot assays employ the quantitative sandwich enzyme-linked immunosorbent assay (ELISA) technique. A monoclonal antibody specific for feline IFN-y has been pre-coated onto a PVDF (polyvinylidene difluoride)-backed microplate. Appropriately stimulated cells are pipetted into the wells and the microplate is placed into a humidified 37 °C CO₂ incubator for a specified period of time. During this incubation period, the immobilized antibody in the immediate vicinity of the secreting cells binds secreted IFN-y. After washing away any cells and unbound substances, a biotinylated polyclonal antibody specific for feline IFN-y is added to the wells. Following a wash to remove any unbound biotinylated antibody, alkaline-phosphatase conjugated to streptavidin is added. Unbound enzyme is subsequently removed by washing and a substrate solution (BCIP/NBT) is added. A blue-black colored precipitate forms and appears as spots at the sites of cytokine localization, with each individual spot representing an individual IFN-y secreting cell. The spots can be counted with an automated ELISpot reader system or manually using a stereomicroscope.

LIMITATIONS OF THE PROCEDURE

- FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
- The kit should not be used beyond the expiration date on the kit label.
- Any variation in pipetting and washing techniques, incubation time or temperature, or kit age can cause variation in density of spots, intensity of specific staining, and background levels.

TECHNICAL HINTS

- To minimize edge effect, place the microplate (bottom down) onto a piece of aluminum foil (about 4 x 6 inches). Add cells, cover the microplate with the lid and shape the foil around the edges of the microplate. The foil may be left on the microplate for the rest of the experimental procedure and removed after the BCIP/NBT has been washed off.
- •Do not touch PVDF membrane filters with pipette tips when pipetting cells and reagents to avoid damage to the membranes.
- •After completion of experiment, do not dry the microplate at a temperature higher than 37° C since it may cause cracking of the PVDF membrane filters.
- •The 96-well microplate provided in the kit is not sterile. However, due to the short incubation period and presence of antibiotics in the culture media, microbial contamination has not been a problem during the ELISpot procedure.
- •The kit is designed for single use only. The layout of the assay should be carefully planned to maximize the use of the plate and reagents provided.
- The controls listed are recommended for each ELISpot experiment:


Positive Control - Use recombinant feline IFN-y.


Unstimulated/Negative Control - Use the same number of unstimulated cells as stimulated cells.

Background Control - Use sterile culture media.


Detection Antibody Control - Substitute phosphate buffered saline for Detection Antibody.

ELISpot SCHEMATIC







Incubate IFN-γ-secreting cells in an antibody-coated well.



Remove cells by washing. Secreted IFN-γ is captured by the immobilized antibody.




Incubate with biotinylated anti-IFN-γ antibody.



Incubate with alkaline phosphatase conjugated streptavidin.

Add BCIP/NBT chromogen



Add substrate and monitor the formation of colored spots.

MATERIALS PROVIDED & STORAGE CONDITIONS

Store the unopened kit at 2-8 °C. Do not use past kit expiration date. This kit is validated for single use only.

Note: Results obtained using previously opened or reconstituted reagents may not be reliable.

PART	PART #	DESCRIPTION
Feline IFN-γ Microplate	892522	96-well PVDF-backed microplate coated with monoclonal antibody specific for feline IFN-y.
Detection Antibody Concentrate	892523	150 μL of a 120X concentrated solution of biotinylated polyclonal antibody specific for feline IFN-γ with preservatives.
Streptavidin-AP Concentrate A	895358	150 μL of a 120X concentrated solution of Streptavidin conjugated to Alkaline Phosphatase with preservatives.
Dilution Buffer 1	895307	12 mL of a buffer for diluting Detection Antibody Concentrate with preservatives.
Dilution Buffer 2	895354	12 mL of a buffer for diluting Streptavidin-AP Concentrate A with preservatives.
Wash Buffer Concentrate	895308	50 mL of a 10X concentrated solution of a buffered surfactant with preservative.
BCIP/NBT Chromogen	895867	12 mL of a stabilized mixture of 5-Bromo-4-Chloro-3' Indolylphosphate p-Toluidine Salt (BCIP) and Nitro Blue Tetrazolium Chloride (NBT).
Feline IFN-γ Positive Control	892524	3 ng of recombinant feline IFN-γ; lyophilized.

OTHER SUPPLIES REQUIRED

- Dissection microscope or an ELISpot reader capable of detecting blue and red spots.
- Pipettes and pipette tips.
- Deionized or distilled water.
- Squirt bottle, manifold dispenser, or automated microplate washer.
- 500 mL graduated cylinder.
- 37 °C CO₂ incubator.
- Sterile culture media.

PRECAUTIONS

BCIP/NBT is toxic if swallowed, in contact with skin, or if inhaled. It is a highly flammable liquid and vapor may cause serious irritation and damage to organs. Do not eat, drink, or smoke when using this product. Do not breathe fumes. Use only in a well-ventilated area. Keep away from heat, sparks, open flames, and hot surfaces. Keep the container tightly closed.

Some components of this kit contain sodium azide, which may react with lead and copper plumbing to form explosive metallic azides. Flush with large volumes of water during disposal.

Some components in this kit contain ProClin® which may cause an allergic skin reaction. Avoid breathing mist.

Do not use reagents from this kit with components from other R&D Systems' ELISpot or ELISA kits and/or components manufactured by other vendors.

Do not remove the flexible plastic underdrain on the bottom of the microplate before or during incubation and development since it may damage the PVDF membrane filters. The underdrain cover may be removed only after completing the incubation with BCIP/NBT chromogen.

Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling. Please refer to the MSDS on our website prior to use.

REAGENT PREPARATION

Bring all reagents to room temperature before use.

Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. To prepare Wash Buffer, add 50 mL of Wash Buffer Concentrate to 450 mL of deionized or distilled water and mix well.

Feline IFN-γ Positive Control - Reconstitute lyophilized feline IFN-γ control with 250 μ L of culture medium that is used to incubate cells.

Detection Antibody - Tap or vortex each vial to release reagent collected in the cap. Transfer 100 µL of Detection Antibody Concentrate into the vial labeled Dilution Buffer 1 and mix well. For optimal performance, prepare the Detection Antibody mixture immediately before use.

Streptavidin-AP - Tap or vortex each vial to release reagent collected in the cap. Transfer 100 μ L of Streptavidin-AP Concentrate A into the vial labeled Dilution Buffer 2 and mix well. For optimal performance, prepare the Streptavidin-AP immediately before use.

SAMPLE PREPARATION

The types of effector and responder cells used, method of cell separation, mode of stimulation, and length of incubation are to be determined by each investigator.

ASSAY PROCEDURE

Bring all reagents to room temperature, except the Detection Antibody Concentrate and Dilution Buffer 1, which should remain at 2-8 °C. All samples and controls should be assayed at least in duplicate. An Assay Record Template is provided at the back of this insert to record controls and samples assayed.

- 1. Fill all wells in the microplate with 200 μ L of sterile culture media and incubate for approximately 20 minutes at room temperature.
- 2. When cells are ready to be plated, aspirate the culture media from the wells. Immediately add 100 μ L of the appropriate cells or controls to each well (see Technical Hints for appropriate controls).
- 3. Incubate cells in a humidified 37 °C CO₂ incubator. Optimal incubation time for each stimuli should be determined by the investigator. **Do not disturb the cells during the incubation period.**
- 4. Aspirate each well and wash, repeating the process three times for a total of four washes. Wash by filling each well with Wash Buffer (250-300 μL) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
 Note: Adjust the height of the prongs of the manifold dispenser or autowasher to prevent damage to the membranes.
- 5. Add 100 μ L of diluted Detection Antibody mixture into each well, and incubate overnight at 2-8 °C.
- 6. Repeat the wash procedure described in step 4.
- 7. Add 100 μ L of diluted Streptavidin-AP into each well, and incubate for 2 hours at room temperature.
- 8. Repeat the wash procedure described in step 4.
- 9. Add 100 μ L of BCIP/NBT Chromogen into each well, and incubate for 1 hour at room temperature. **Protect from light.**
- 10. Discard the chromogen solution from the microplate and rinse the microplate with deionized or distilled water. Invert the microplate and tap to remove excess water. Remove the flexible plastic underdrain from the bottom of the microplate, wipe the bottom of the plate thoroughly with paper towels and dry completely either at room temperature (60-90 minutes) or 37 °C (15-30 minutes).

CALCULATION OF RESULTS

The developed microplate can be analyzed by counting spots either manually using a dissection microscope or by using a specialized automated ELISpot reader. Specific spots are round and have a dark center with slightly fuzzy edges. Quantitation of results can be done, for example, by calculating the number of spot forming cells (SFC) per number of cells added into the well.

REPRODUCIBILITY DATA

Feline peripheral blood mononuclear cells (1 x 10^5 cells/mL) were stimulated with 50 ng/mL of phorbol 12-myristate-13-acetate (PMA) and 0.5 μ g/mL of calcium ionomycin overnight at 37 °C in a 5% CO₂ incubator. The sample was assayed in seven wells according to the procedure and analyzed with a dissection microscope.

Well	Number of Spots Counted
1	164
2	176
3	168
4	165
5	158
6	176
7	169

TROUBLESHOOTING GUIDE

OBSERVATION	PROBLEM	CORRECTIVE ACTION
Following the incubation with BCIP/NBT chromogen and rinsing the microplate with deionized or distilled water, the dark blue background color of the filter membrane attenuates visualization and quantitation of spots.	The membrane is wet.	Microplates cannot be analyzed accurately until the PVDF filter membranes are completely dry. Wait until the membrane becomes dry (typically 15-30 minutes at 37 °C or 60-90 minutes at room temperature).
The number of spots in the wells that contained the cells is high, but their contrast as well as intensity of staining in the Positive Control wells is low.	Underdevelopment; perhaps the result of using Streptavidin-AP and/ or BCIP/NBT solutions that have not been brought to room temperature.	Warm the appropriate reagents to room temperature before adding them to the wells.
The number of spots in the wells that contained cells is lower than expected whereas Positive Control wells turned blue-black.	Cell stimulation problem.	Ensure that reagents used to stimulate the cytokine release from the cells retained their biological activity. One way to check is to perform immunocytochemistry on fixed cells after stimulation.
	Too few cells were added to the wells.	Increase the number of cells added per well.
Following incubation with BCIP/NBT and drying the microplate, the density of the spots makes them difficult to quantify.	Too many cells were added to the wells.	Make dilutions of cells (1 x 10^6 , 5 x 10^5 , 1 x 10^5 , 5 x 10^4 , 1 x 10^4 cells per well) to determine the optimal number of cells that will result in formation of distinct spots.


All trademarks and registered trademarks are the property of their respective owners.

REFERENCES

- 1. Wheelock, E.F. (1965) Science **146**:310.
- 2. Billiau, A. (1996) Adv. Immunol. 62:61.
- 3. Farrar, M.A. and R.D. Schreiber (1993) Annu. Rev. Immunol. 11:571.
- 4. Paludan, S.R. (1998) Scand, J. Immunol. 48:459.
- 5. Boehm, U. et al. (1997) Annu. Rev. Immunol. 15:749.
- 6. Sugaya, M. et al. (1999) J. Invest. Dermatol. 113:350.
- 7. Howie, S.E.M. et al. (1996) J. Invest. Dermatol. 106:1218.
- 8. Battistini, L. et al. (1997) J. Immunol. **159**:3723.
- 9. Gupta, A.A. et al. (1996) J. Immunol. 157:2123.
- 10. Neumann, H. et al. (1997) J. Exp. Med. **186**:2023.
- 11. Hoiden, I. and G. Moller (1996) Scand. J. Immunol. 44:501.
- 12. Puddu, P. et al. (1997) J. Immunol. 159:3490.
- 13. Yoshimoto, T. et al. (1997) Proc. Natl. Acad. Sci. USA **94**:3948.
- 14. Yeaman, G.R. et al. (1998) J. Immunol. 160:5145.
- 15. Asea, A. et al. (1996) Clin. Exp. Immunol. 105:376.
- 16. Briscoe, D.M. et al. (1997) J. Immunol. 159:3247.
- 17. Dejuco, N. et al. (1995) Endocrinology **136**:4925.
- 18. Lebel-Binay, S. et al. (2000) Eur. Cytokine Netw. **11**:15.
- 19. Tominaga, K. et al. (2000) Int. Immunol. **12**:151.
- 20. Trinchieri, G. and F. Gerosa (1996) J. Leukoc. Biol. **59**:505.
- 21. Oppmann, B. et al. (2000) Immunity **13**:715.
- 22. Schijns, V.E.C.J. et al. (1995) Immunogenetics **42**:440.
- 23. Dijkema, R. et al. (1985) EMBO J. **4**:761.
- 24. Dijemka, R. et al. (1986) Methods Enzymol. 119:453.
- 25. Gray, P.W. and D.V. Goeddel (1983) Proc. Natl. Acad. Sci. USA 80:5842.
- 26. Gray, P.W. and D.V. Goeddel (1982) Nature **298**:859.
- 27. Taya, Y. et al. (1982) EMBO J. 1:953.
- 28. Bach, E.A. et al. (1997) Annu. Rev. Immunol. 15:563.
- 29. Marsters, S.A. et al. (1995) Proc. Natl. Acad. Sci. USA **92**:5401.
- 30. Thiel, D.J. et al. (2000) Structure **8**:927.
- 31. Lembo, D. et al. (1996) J. Biol. Chem. 271:32659.
- 32. Czerkinsky, C.C. et al. (1983) J. Immunol. Methods 65:109.
- 33. Sedgwick, J.D. and P.G. Holt (1983) J. Immunol. Methods **57**:301.
- 34. Czerkinsky, C.C. et al. (1984) J. Immunol. Methods **72**:489.
- 35. Helms, T. et al. (2000) J. Immunol. 164:3723.

PLATE LAYOUT

Use this plate layout to record controls and samples assayed.



©2014 R&D Systems, Inc.

02.13 751021.5 3/14